Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Exelixis Inc (EXEL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 5,161,940
  • Shares Outstanding, K 230,330
  • Annual Sales, $ 37,170 K
  • Annual Income, $ -169,740 K
  • 36-Month Beta 1.78
  • Price/Sales 41.41
  • Price/Book 128.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.22 +26.02%
on 01/03/17
19.30 -7.15%
on 01/13/17
+1.36 (+8.21%)
since 12/20/16
3-Month
10.04 +78.49%
on 11/03/16
19.30 -7.15%
on 01/13/17
+6.18 (+52.64%)
since 10/20/16
52-Week
3.55 +404.79%
on 03/17/16
19.30 -7.15%
on 01/13/17
+13.42 (+298.22%)
since 01/20/16

Most Recent Stories

More News
Investors: Covered-Call Reports for BB&T Corporation, Exelixis, Merck & Company Incorporated, Parsley Energy Inc and Workday

InvestorsObserver issues critical PriceWatch Alerts for BBT, EXEL, MRK, PE, and WDAY.

4 Stocks in Focus as Biotech M&A Hopes Surge on Takeda-ARIAD Deal

Takeda to Buy ARIAD, More M&As to Follow in Biotech Sector?

Biotech Stocks to Watch in 2017 ACADIA Pharmaceuticals and Exelixis

NEW YORK, NY / ACCESSWIRE / January 4, 2017 / The Biotech Industry posted a sharp loss in 2016 as concerns over price gouging plagued the Industry. The iShares NASDAQ Biotechnology Index ETF (IBB) fell...

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (NASDAQ:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 17,750 shares of Exelixis common stock, and stock options to...

4 Biotech Stocks with Bright Prospects in 2017

Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017....

The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

The Zacks Analyst Blog Highlights: CoLucid Pharmaceuticals, Exelixis, TESARO and Achaogen

Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx

Exelixis, Inc. (EXEL) announced that it has amended the exclusive collaboration and licensing agreement with its European partner Ipsen.

4 Biotech Stocks that More than Doubled in 2016

Despite the immense pressure on the sector, there were some biotech stocks that bucked the trend and more than doubled in 2016.

Exelixis and Ipsen Amend Exclusive Licensing Agreement for the Commercialization and Development of Cabozantinib to Include Canada

-- Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Ophthotech and Exelixis

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another...

See More

Support & Resistance

2nd Resistance Point 18.25
1st Resistance Point 18.09
Last Price 17.92
1st Support Level 17.70
2nd Support Level 17.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.